FRANKFURT (Reuters) - German drugmaker Merck KGaA's cancer vaccine Stimuvax has failed to meet its goal of improving the survival of lung cancer patients in a late-stage trial. "It is disappointing that the... trial did not meet its primary endpoint, in particular for patients suffering from NSCLC (non-small cell lung cancer)," the trial's coordinating investigator, Frances Shepherd, said in a statement on Wednesday. ... Continue reading...
No comments:
Post a Comment